Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2014 Mar 4;5:3374. doi: 10.1038/ncomms4374

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2014, Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.

This work is licensed under a Creative Commons Attribution 3.0 Unported License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit http://creativecommons.org/licenses/by/3.0/

PMC Copyright notice

(a,b) Systemic administration of the selective mGlu5R antagonist MTEP (open triangle; 3 mg kg⁻¹, i.p.) completely prevented the induction of LTD by LFS-300 (bar) in animals injected i.c.v. with soluble Aβ_1–42 (hash) (68.6±4.0% in the vehicle+Aβ group, n=5, P<0.05 compared with Pre, and compared with 98.4±7.6% in the MTEP+Aβ group, n=5, P>0.05 compared with Pre; t-tests). (c,d) Similarly, MTEP completely prevented the induction of LTD in animals injected with Aβ-containing AD brain extract. As summarized in (d) the EPSP measured 76.2±3.6% in the vehicle+AD group, n=4, (P<0.05 compared with Pre, and compared with 97.4 ±5.6% in the MTEP+AD group, n=4, P>0.05 compared with Pre; t-tests). (e,f) In contrast, the same dose of MTEP that prevented Aβ-facilitated LTD failed to significantly affect control LTD induced by LFS-900 (72.0±4.4% in the vehicle+vehicle group, n=11, P<0.05 compared with Pre, and P>0.05 compared with 80.6±7.2% in the MTEP+vehicle group, n=5, P<0.05 compared with Pre; t-tests). (g,h) i.c.v. injection of soluble Aβ_1–42 (hash), at the dose that facilitated LTD, blocked LTP completely at 3 h post HFS. Although systemic administration of MTEP (3 mg kg⁻¹) did not affect HFS-induced control LTP, it prevented Aβ-mediated impairment of LTP. As summarized in (h), HFS induced significant (P<0.05 compared with Pre; paired t) LTP in the vehicle control group (132.7±4.0%, n=5), MTEP+vehicle group (131.5±5.2%, n=4) and MTEP+Aβ group (120.6±3.4%, n=8), but not in the vehicle+Aβ group (96.2±4.7%, n=5), which was significantly different from the other groups (one-way ANOVA-Tukey). Values are mean±s.e.m. Calibration: vertical, 2 mV; horizontal, 10 ms.